Signal transducer and activator of transcription 3 (STAT3) is the JAK-STAT pathway's most multipurpose member: cytoplasmic monomers that receptor-associated JAK kinases phosphorylate on a single tyrosine, whereupon they dimerise (SH2-to-phosphotyrosine reciprocal handshake) and enter the nucleus to bind GAS elements and switch on cytokine-response genes. IL-6's inflammatory program, gp130 signalling, and growth-factor routes all use it; its constitutive activation in tumors (the "STAT3 oncogene" — driving proliferation, survival, angiogenesis, and immune evasion) made it one of oncology's most-wanted transcription factors.
Gene
STAT3 (17q21.2)
Family
STAT family (STAT1–6 in humans)
Location
Cytoplasm → nucleus after tyrosine phosphorylation
JAKs, receptor phosphotyrosines, reciprocal pY705-SH2, DNA GAS sites
Structure
The modular domain architecture ends in the SH2 domain and the C-terminal Tyr705 — phosphorylation flips the monomers into parallel dimers via each SH2 gripping the other's phosphotyrosine.
Ser727 phosphorylation (by MAPKs and mTOR) tunes transcriptional output — a second, modulatory input; see MAPK crosstalk.
Crystal structures of the dimer on DNA showed the bent-reptation of the STAT bind — the field's founding image.
Function
IL-6 axis: IL-6 and related cytokines drive STAT3's acute-phase, inflammation, and Th17 programs — autoimmunity's favorite route; see immune system.
Development: STAT3 is essential (knockout mice die embryonically) for gastrulation, and later for mammary involution, neutrophil survival, and gut epithelial wound-sensing (IL-22 → STAT3).
Non-canonical roles: mitochondrial STAT3 modulates respiration; granzyme-cleaved forms signal differently — the protein keeps surprising.
Regulation
SOCS proteins (induced by STAT itself) and PIAS inhibitors are the built-in brakes; phosphatases strip pY705 within minutes — homeostatic feedback.
Upstream, JAKs (JAK1/JAK2/TYK2) at gp130 and cytokine receptors are the kinases; JAK inhibitors (baricitinib, ruxolitinib) cut STAT3 signals in practice.
PTEN's PI3K-AKT route and STAT3 signalling synergise in tumors — the double-lesion logic of Akt-driven survival.
Interactions
With NF-κB it co-occupies inflammatory gene loci; with HIF-1α and VEGF induction it shapes the tumor microenvironment.
IL-22/STAT3 in gut epithelium and Treg-associated IL-10/STAT3 signalling are the immune-tolerance faces of the same molecule.
Growth-factor receptors (EGFR-family) phosphorylate STAT3 directly — a kinase-to-transcription-factor shortcut, see EGFR.
Clinical Relevance
Autoinflammation: gain-of-function STAT3 mutations cause early-onset multisystem autoimmune disease; loss-of-function causes Hyper-IgE (Job's) syndrome — the gene's genetic proof of versatility.
Cancer: constitutive STAT3 marks many solid tumors and myeloma; direct inhibitors (STAT3 SH2 binders) remain hard, so upstream JAK blockade carries the clinic — ruxolitinib in myelofibrosis.
Immunosuppression target: tumor STAT3's suppression of dendritic-cell activity is the immunotherapy rationale for the pathway's inhibitors.